[1] |
XIE YD, ZHAO CQ, WANG JP, et al. Alcohol consumption analysis among patients with liver disease in China[J]. Chin Med J (Engl), 2019, 132(4): 420-430. DOI: 10.1097/CM9.0000000000000067.
|
[2] |
IPSEIZ N, PICKERING RJ, ROSAS M, et al. Tissue-resident macrophages actively suppress IL-1beta release via a reactive prostanoid/IL-10 pathway[J]. EMBO J, 2020, 39(14): e103454. DOI: 10.15252/embj.2019103454.
|
[3] |
MUÑOZ-PLANILLO R, KUFFA P, MARTÍNEZ-COLÓN G, et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter[J]. Immunity, 2013, 38(6): 1142-1153. DOI: 10.1016/j.immuni.2013.05.016.
|
[4] |
TALTY A, DEEGAN S, LJUJIC M, et al. Inhibition of IRE1α RNase activity reduces NLRP3 inflammasome assembly and processing of pro-IL1β[J]. Cell Death Dis, 2019, 10(9): 622. DOI: 10.1038/s41419-019-1847-z.
|
[5] |
BUSCETTA M, di VINCENZO S, MIELE M, et al. Cigarette smoke inhibits the NLRP3 inflammasome and leads to caspase-1 activation via the TLR4-TRIF-caspase-8 axis in human macrophages[J]. FASEB J, 2020, 34(1): 1819-1832. DOI: 10.1096/fj.201901239R.
|
[6] |
KARMAKAR M, MINNS M, GREENBERG EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis[J]. Nat Commun, 2020, 11(1): 2212. DOI: 10.1038/s41467-020-16043-9.
|
[7] |
JAKKA P, NAMANI S, MURUGAN S, et al. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages[J]. J Biol Chem, 2017, 292(50): 20613-20627. DOI: 10.1074/jbc.M117.815878.
|
[8] |
RV HL S, BROZ P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux[J]. Eur J Immunol, 2015, 45(10): 2927-2936. DOI: 10.1002/eji.201545772.
|
[9] |
MAHMUTOVIC PERSSON I, MENZEL M, RAMU S, et al. IL-1β mediates lung neutrophilia and IL-33 expression in a mouse model of viral-induced asthma exacerbation[J]. Respir Res, 2018, 19(1): 16. DOI: 10.1186/s12931-018-0725-z.
|
[10] |
DING Z, WANG X, LIU S, et al. NLRP3 inflammasome via IL-1β regulates PCSK9 secretion[J]. Theranostics, 2020, 10(16): 7100-7110. DOI: 10.7150/thno.45939.
|
[11] |
MANDREKAR P, SZABO G. Signalling pathways in alcohol-induced liver inflammation[J]. J Hepatol, 2009, 50(6): 1258-1266. DOI: 10.1016/j.jhep.2009.03.007.
|
[12] |
ZHAO J, QI YF, YU YR. Research advances in the role of oxidative stress in the development and progression of liver fibrosis[J]. J Clin Hepatol, 2019, 35(9): 2067-2071. DOI: 10.3969/j.issn.1001-5256.2019.09.040.
赵杰, 齐永芬, 鱼艳荣. 氧化应激在肝纤维化发生发展中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2067-2071. DOI: 10.3969/j.issn.1001-5256.2019.09.040.
|
[13] |
AL-SADI R, GUO S, YE D, et al. Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation[J]. J Immunol, 2013, 190(12): 6596-6606. DOI: 10.4049/jimmunol.1201876.
|
[14] |
PETRASEK J, BALA S, CSAK T, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice[J]. J Clin Invest, 2012, 122(10): 3476-3489. DOI: 10.1172/JCI60777.
|
[15] |
STIENSTRA R, SAUDALE F, DUVAL C, et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity[J]. Hepatology, 2010, 51(2): 511-522. DOI: 10.1002/hep.23337.
|
[16] |
GLUCHOWSKI NL, GABRIEL KR, CHITRAJU C, et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl coA: Diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice[J]. Hepatology, 2019, 70(6): 1972-1985. DOI: 10.1002/hep.30765.
|
[17] |
STANTON MC, CHEN SC, JACKSON JV, et al. Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice[J]. J Inflamm (Lond), 2011, 8: 8. DOI: 10.1186/1476-9255-8-8.
|
[18] |
IRACHETA-VELLVE A, PETRASEK J, SATISHCHANDRAN A, et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice[J]. J Hepatol, 2015, 63(5): 1147-1155. DOI: 10.1016/j.jhep.2015.06.013.
|
[19] |
CUI K, YAN G, XU C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice[J]. J Hepatol, 2015, 62(6): 1311-1318. DOI: 10.1016/j.jhep.2014.12.027.
|
[20] |
ILYAS G, CINGOLANI F, ZHAO E, et al. Decreased macrophage autophagy promotes liver injury and inflammation from alcohol[J]. Alcohol Clin Exp Res, 2019, 43(7): 1403-1413. DOI: 10.1111/acer.14041.
|
[21] |
WANG H, ZHOU H, ZHANG Q, et al. Inhibition of IRAK4 kinase activity improves ethanol-induced liver injury in mice[J]. J Hepatol, 2020, 73(6): 1470-1481. DOI: 10.1016/j.jhep.2020.07.016.
|
[22] |
LEE J H, SHIM Y R, SEO W, et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcoholic liver injury[J]. Hepatology, 2020, 72(2): 609-625. DOI: 10.1002/hep.31041.
|
[23] |
PETRASEK J, DOLGANIUC A, CSAK T, et al. Type interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice[J]. Gastroenterology, 2011, 140(2): 697-708. e4. DOI: 10.1053/j.gastro.2010.08.020.
|
[24] |
GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041.
|
[25] |
ALEGRE F, PELEGRIN P, FELDSTEIN A. Inflammasomes in liver fibrosis[J]. Seminars in liver disease, 2017, 37(2): 119-127. DOI: 10.1055/s-0037-1601350.
|
[26] |
REITER FP, WIMMER R, WOTTKE L, et al. Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model[J]. World J Hepatol, 2016, 8(8): 401-410. DOI: 10.4254/wjh.v8.i8.401.
|
[27] |
YAPING Z, YING W, LUQIN D, et al. Mechanism of interleukin-1β-induced proliferation in rat hepatic stellate cells from different levels of signal transduction[J]. APMIS, 2014, 122(5): 392-398. DOI: 10.1111/apm.12155.
|
[28] |
PRADERE JP, KLUWE J, de MINICIS S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice[J]. Hepatology, 2013, 58(4): 1461-1473. DOI: 10.1002/hep.26429.
|
[29] |
KAMARI Y, SHAISH A, VAX E, et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice[J]. J Hepatol, 2011, 55(5): 1086-1094. DOI: 10.1016/j.jhep.2011.01.048.
|
[30] |
DINARELLO CA, SIMON A, van DER MEER JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases[J]. Nat Rev Drug Discov, 2012, 11(8): 633-652. DOI: 10.1038/nrd3800.
|
[31] |
SZABO G, PETRASEK J, BALA S. Innate immunity and alcoholic liver disease[J]. Dig Dis, 2012, 30(Suppl 1): 55-60. DOI: 10.1159/000341126.
|
[32] |
GEHRKE N, HÖVELMEYER N, WAISMAN A, et al. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation[J]. J Hepatol, 2018, 68(5): 986-995. DOI: 10.1016/j.jhep.2018.01.008.
|
[33] |
SHIRASUGI N, WAKABAYASHI G, SHIMAZU M, et al. Up-regulation of oxygen-derived free radicals by interleukin-1 in hepatic ischemia/reperfusion injury[J]. Transplantation, 1997, 64(10): 1398-1403. DOI: 10.1097/00007890-199711270-00004.
|
[34] |
RIDKER PM, MACFADYEN JG, THUREN T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2017, 390(10105): 1833-1842. DOI: 10.1016/S0140-6736(17)32247-X.
|
[35] |
DHIMOLEA E. Canakinumab[J]. MAbs, 2010, 2(1): 3-13. DOI: 10.4161/mabs.2.1.10328.
|